[A19-57] Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 15.10.2019

Project no.:

Commission awarded on 11.07.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Monotherapy of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer

Result of dossier assessment:

Without prior chemotherapy for metastatic breast cancer: indication of considerable added benefit; with prior chemotherapy for metastatic breast cancer: hint of considerable added benefit


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form